Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Eftrenonacog alfa - Bioverativ/Swedish Orphan Biovitrum

Drug Profile

Eftrenonacog alfa - Bioverativ/Swedish Orphan Biovitrum

Alternative Names: Alprolix; BIIB-029; Coagulation factor IX recombinant immunoglubulin G1 fusion protein; Eftrenonacog alfa; Factor IX-Fc; FIX-Fc; Recombinant factor IX Fc; rFIXFc

Latest Information Update: 17 Sep 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Syntonix Pharmaceuticals
  • Developer Biogen; Bioverativ; Swedish Orphan Biovitrum
  • Class Blood coagulation factors; Recombinant fusion proteins
  • Mechanism of Action Blood coagulation factor replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Haemophilia B
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Haemophilia B

Most Recent Events

  • 20 Aug 2019 Bioverativ Therapeutics completes a phase III trial in Haemophilia B (In adolescents, In children, In infants, In neonates) in Australia, Belgium, Czech Republic, Denmark, England, France, Germany, Ireland, Italy, Netherlands, New Zealand, Poland, Spain, Sweden, Switzerland, UK and USA (IV) (EudraCT2013-003629-27; NCT02234310)
  • 09 Jul 2019 Efficacy data from a phase III B-YOND/B-LONG trial in Haemophilia B released by Sobi and Sanofi
  • 02 Dec 2018 Final results from the phase III B-YOND trial in Haemophilia B released by Orphan Biovitrum
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top